ANALYSIS: Inotiv Liquidity Deteriorates Amid RMS Weakness, Structural Cash Burn; Waiver Reliance Leaves 2026 Maturities Dependent on Lender Support

Relevant Items:
Inotiv Lenders Grant Waiver of Minimum Liquidity Covenant
Life Sciences Quarterly, Part 1
Life Sciences Quarterly, Part 2
Historical Financials
Excel Model
 

 

• Inotiv, a midmarket contract research organization, or CRO, providing nonclinical drug development services and research models to the pharmaceutical industry, has a capital structure that appears unsustainable absent lender support, new capital or a negotiated refinancing, with near-term maturities and advisor activity underscoring refinancing pressure.
  

  The company has approximately $439.4 million of total debt against only $33.2 million of LTM adjusted EBITDA, implying approximately 12.9x net leverage and interest coverage below 1x. First lien debt is due in November 2026, second lien senior secured notes are due in February 2027 and convertible notes are due in October 2027.

  
  

  Secondary trading reflects this pressure, with the term loan trading at about 86 and convertible notes at about 10, according to IHS Markit, while Inotiv’s engagement of Perella Weinberg and BRG’s retention by an ad hoc lender group signal increasing refinancing activity ahead of maturities.
  
   

• Liquidity is thin, covenant-dependent and likely overstated by headline revolver availability. As of Dec. 31, 2025, Inotiv had approximately $21.7 million of liquidity, including $12.7 million of cash and $9 million of RCF availability, below the amended $30 million minimum liquidity covenant effective March 2026.
  

  The company has since relied on repeated short-term waivers, while near-term obligations, including a $5 million Department of Justice-related payment due June 3, 2026, further pressure liquidity and limit runway ahead of the November 2026 first lien maturity.
  
   

• The research models and services, or RMS, segment remains the core operating pressure point facing continued negative volumes. Revenue has remained broadly flat, but approximately 62% is tied to RMS, a product-heavy and working-capital-intensive segment exposed to nonhuman primate, or NHP, volumes, pricing normalization, tariffs and quarantine cycles.
  

  NHP volumes declined approximately 25% year over year in the first quarter of 2026, while tariff costs of 15% to 20% and weaker operating leverage continue to weigh on margins. Adjusted EBITDA margins fell to 3.7% in FY 2024 from approximately 16.5% in FY 2022, recovered only to 6.6% in FY 2025, and compressed again to approximately 1.5% in first-quarter 2026.
  
   

• Structural cash burn limits Inotiv’s ability to address near-term maturities organically. Over the LTM period, Inotiv generated approximately $26.2 million of unlevered operating cash flow, but this was more than offset by $37.6 million of cash interest and $17.3 million of capital expenditures, resulting in approximately $29 million of levered free cash outflow. With cash interest exceeding adjusted EBITDA, the company lacks sufficient internal cash generation to fund operations, service debt and bridge to the 2026 maturity wall.

 

Near-Term Maturity Wall Leaves Limited Runway for Operational Recovery

Inotiv’s capital structure is effectively current, with first lien maturities approaching in November 2026 and second lien secured notes due shortly thereafter in February 2027. Total debt stands at approximately $439.4 million as of Dec. 31, 2025, with net leverage of approximately 12.9x and interest coverage below 1x. The capital structure consists of $267.4 million of senior secured term loans, alongside a $15 million revolving credit facility, of which $6 million was drawn, both maturing in November 2026.

Behind the first lien debt, Inotiv has $24.7 million of second lien 15% senior secured notes, due February 2027, followed by $114.8 million of 3.25% convertible notes due October 2027.

In addition, approximately $17 million remains outstanding under a resolution and plea agreement with the U.S. Department of Justice, arising from animal welfare violations at Envigo RMS LLC, which Inotiv acquired in November 2021, establishing the company’s RMS segment. These obligations are payable in installments of $5 million annually on June 3, 2026, and June 3, 2027, with a final payment of approximately $7 million, plus accrued interest, due on June 3, 2028.

Inotiv’s capital structure as of the first quarter ended Dec. 31 is shown below:
 

Historical pricing for the company’s term loan and convertible notes is below:
 

Liquidity Is Thin, Dependent on Lender Support

Liquidity totaled $21.7 million as of Dec. 31, 2025, including $12.7 million of cash and $9 million of availability under the RCF. Cash declined by approximately $9 million, or 41.5%, from Sept. 30, 2025, driven by sustained negative free cash flow and partially offset by incremental revolver borrowings.

On Feb. 8, Inotiv and its lenders entered into an eighth amendment to the credit agreement, which increased the minimum liquidity covenant to $30 million from $10 million, effective March 6, with weekly testing. Based on Dec. 31 liquidity of $21.7 million, Inotiv was approximately $8.3 million below the revised threshold, indicating immediate covenant noncompliance absent lender intervention.

Subsequent disclosures confirm reliance on repeated short-term waivers of the minimum liquidity covenant through March and April. This follows prior breaches of the first lien leverage ratio and fixed-charge coverage ratio, which were waived for the first-quarter 2026.

This liquidity pressure is further intensified by ongoing free cash flow burn, weak EBITDA coverage of cash interest and upcoming required payments, including a $5 million DOJ-related payment due June 3. With first lien debt maturing in less than a year from the reporting date in November 2026, the company has limited room to absorb further operating volatility. These structural headwinds will be further explained in the sections below.
 

Flat Revenue Driven by Unbalanced Segment Mix and Weak RMS Performance

Inotiv’s revenue has been range-bound since 2022. Revenue totaled approximately $514 million on an LTM basis as of Dec. 31. This flat performance, however, masks increasing divergence between the company’s two operating segments – discovery and safety assessment, or DSA, and research models and services, or RMS.

Inotiv’s revenue breakdown by segment is shown below:
 

 

The DSA segment, which accounts for approximately 38% of total revenue, is primarily a service-based business, with approximately 97% of segment revenue derived from services providing early-stage discovery, bioanalytical and nonclinical safety-testing services under fixed-fee and milestone-based contracts. Although DSA has shown signs of recovery, with first-quarter 2026 revenue increasing approximately 12% year over year and backlog expanding to $145.4 million, revenue visibility is sensitive to customer funding and project timing.

Performance has been affected by elevated cancellations and negative change orders, driven by a broader decline in biotech funding activity and client spending, as well as the concentration risk of one or two large individual cancellations in any given quarter. Cancellations and negative change orders in the first quarter were approximately 51% lower year over year, with trailing 12-month cancellations approximately 17% lower than the prior-year period.

This improvement has been supported by strengthening commercial execution, including expansion of the discovery and safety sales organization, increased penetration in key biotech markets and higher net new awards, which increased more than 27% year over year in the first-quarter 2026 and more than 34% on a trailing 12-month basis ended Dec. 31, 2025, according to Inotiv’s February 2026 investor presentation.

In contrast, the RMS segment, which accounts for approximately 62% of total revenue, is predominantly a product-driven business, with approximately 84% of segment revenue derived from product sales, including research models such as NHP and rabbits, as well as consumables such as diets and bedding, alongside a smaller contribution from related services. This segment is inherently more volatile and working capital-intensive, remaining the primary driver of earnings pressure.

RMS performance deteriorated materially from FY 2023 and volumes continue to fall. First-quarter 2026 revenue declined approximately 5.4% year over year, driven primarily by a roughly 25% decline in NHP volumes year over year, partially offset by higher average selling prices and increased NHP-related services revenue. This follows a sharp decline in FY 2024, when RMS revenue decreased approximately 20% year over year, largely attributable to the NHP product business.

The year-over-year deterioration in 2024 reflects a combination of volume and pricing dynamics. Following the disruption of the Cambodian NHP supply in late 2022, NHP prices increased significantly through FY 2023 as supply tightened. As alternative supply sources came online in FY 2024, both procurement costs and selling prices declined.

However, improved supply did not translate into a volume recovery, as FY 2023 demand had been supported by scarcity-driven purchasing and inventory buildup, with customers subsequently normalizing purchases around near-term needs. As a result, RMS faced both lower NHP pricing and weak volumes, limiting revenue recovery despite improved availability.

The pricing normalization created a double impact on revenue and margins, as lower selling prices reduced revenue per unit while higher-cost inventory from the prior-year period compressed margins. The NHP-related revenue decline accounted for approximately $60.4 million of the total revenue decrease in FY 2024. This was compounded by the August 2023 divestiture of the company’s Israeli businesses, which removed approximately $10.6 million of RMS revenue, further contributing to the year-over-year decline.

RMS revenue improved modestly in FY 2025, driven by a $14.3 million increase in NHP product and service revenue, attributable to higher average selling prices and partially offset by a $5.3 million decline in small animal revenue due to lower volumes sold and a $3 million decrease in diet, bedding and enrichment revenue. RMS gross margin improved to approximately 17% in FY 2025 from 14% in FY 2024 and remained about 17% on an LTM basis as of Dec. 31. First-quarter 2026 gross margin compressed to approximately 10% as NHP volumes declined 25% year over year, while adjusted EBITDA margin fell to approximately 1.5%.

Management indicated on the first-quarter 2026 earnings call that full-year 2026 NHP revenue is expected to remain relatively flat, reflecting ongoing volume constraints.

NHP Volume Volatility, Tariffs and Fixed Costs Limit Margin Recovery

Inotiv’s margin profile remains highly sensitive to NHP volumes and pricing. Adjusted EBITDA declined from $90.5 million in FY 2022 to $65.8 million in FY 2023 and $18.2 million in FY 2024, while adjusted EBITDA margin compressed from 16.5% to 11.5% and 3.7%, respectively.

Although adjusted EBITDA recovered to $33.9 million in FY 2025, margins remained well below peak levels, at 6.6%, and compressed again to approximately 1.5% in first-quarter 2026, reflecting renewed NHP volume pressure.
 

Margin compression has been driven primarily by lower NHP volumes, tariff pressure and the fixed-cost nature of the RMS platform. Although higher average selling prices partially offset lower NHP volumes in first-quarter 2026, the volume decline reduced operating leverage, as facility, labor, quarantine and logistics costs were spread across a smaller revenue base. As a result, pricing was insufficient to offset the impact of weaker volumes and higher procurement costs on profitability.

Tariffs, which are mainly on imported NHPs, ranged from 10% to 20% in FY 2025, increased to 15% to 20% in first-quarter 2026 and continue to weigh on RMS margins. Although pricing dynamics were driven primarily by prior supply shortages rather than tariffs, margin benefits have been limited as tariff-related cost increases and elevated inventory costs offset any pricing tailwinds.

In addition, tariffs are payable within approximately 30 days of import, a timeline shorter than the average NHP inventory turnover cycle, creating a working capital burden and limiting the company’s ability to scale volumes efficiently.

Although supply has improved from alternative sources, Inotiv remains reliant on imported NHPs, as domestic U.S. supply has not materially expanded, and Cambodia remains effectively unavailable, requiring continued imports to maintain inventory levels and operational efficiency. Although management has indicated it is working with suppliers and customers to mitigate these costs, the effectiveness of these efforts remains uncertain.

In response to margin pressures, Inotiv is pursuing cost-optimization initiatives to reduce its fixed-cost base. The company is consolidating its RMS small animal production footprint to approximately 11 locations by spring 2026 from 23, and this is expected to generate $6 million to $7 million of annual cost savings upon completion. In addition, Inotiv has taken steps to optimize its logistics network, including insourcing North American transportation and implementing delivery and route efficiencies.

Management, however, has indicated that the benefits of these initiatives are being offset by lower NHP volumes, limiting their near-term impact on profitability.
 

 

Inotiv has struggled to maintain positive FCF despite generating modest unlevered operating cash flow. On an LTM basis ended Dec. 31, the company generated approximately $26.2 million of unlevered operating cash flow, before cash interest, which was more than offset by $37.6 million of cash interest and approximately $17.3 million of capital expenditures, resulting in levered free cash of approximately negative $29 million.

Capital expenditures in FY 2025 were primarily driven by facility improvements related to animal welfare compliance and capacity expansions to support future NHP colony management service revenue, indicating that a portion of spending is tied to regulatory requirements and long-term operational needs and is therefore likely to persist.
 

Working capital dynamics, particularly within the NHP business, continue to create volatility and delay cash conversion. As noted earlier, Inotiv pays for NHP imports upfront, with tariffs of approximately 15% to 20% due within 30 days, while animals must complete quarantine before sale and customer payments are collected over time, resulting in a timing mismatch where cash outflows occur significantly in advance of inflows. This has been further compounded by a reversal in working capital, including a $14.5 million reduction in fees invoiced in advance in first-quarter 2026, reflecting a drawdown of customer prepayments and an additional drag on operating cash flow.

This dynamic is reflected in the company’s cash conversion cycle, which remains elevated at approximately 43.2 days LTM as of first-quarter 2026, despite improvement from prior periods. Days sales outstanding declined to 42 days, while inventory days remain elevated at 74 days, reflecting NHP holding and quarantine cycles. Days payable outstanding is still high at 71 days, indicating some supplier extension.

Overall, the positive cash conversion cycle underscores the structural working-capital intensity of the RMS segment and the lag between cash outflows and revenue realization.
 

Prior Octus sector analysis noted that Inotiv would likely seek to extend its runway and potentially bolster liquidity as it maintains higher NHP inventory levels. We agree with that view, as higher inventory may support customer supply stability but also ties up cash, increases tariff-related working capital needs and extends the lag between cash outflows and revenue conversion.

Additional liquidity would help bridge this timing mismatch but would not solve the broader issue that the business is not generating enough earnings to cover its fixed cash obligations. This is reflected in capital expenditures and cash interest, which continue to consume cash despite the company’s cost-reduction efforts.

Capital expenditures remain a meaningful use of cash, with LTM spending of approximately $17.5 million to support RMS consolidation and operational upgrades, as noted earlier. Although these initiatives are intended to improve long-term efficiency, they continue to weigh on near-term free cash flow given the company’s limited earnings base.

Interest burden represents the largest structural drag on cash flow. On an LTM basis, cash interest of $37.6 million exceeds adjusted EBITDA of $33.2 million, effectively consuming all internally generated cash flow. As a result, Inotiv remains reliant on external financing, including revolver borrowings, to fund ongoing cash burn, underscoring constrained financial flexibility and increasing dependence on lender support. This reliance is already reflected in the company’s revolver usage, with Inotiv drawing $3 million on its RCF during FY 2025 and an additional $3 million in first-quarter 2026, bringing the outstanding balance to $6 million as of Dec. 31, 2025.
 

A prior Octus life sciences sector analysis noted a more constructive 2026 backdrop for life sciences credits, supported by improving biotech funding, reduced pipeline reprioritization risk and a more stable biopharma spending environment following a period of vendor consolidation and pipeline reassessment through 2024 and early 2025.

This constructive tone is also supported by peer commentary. On Charles River Laboratories’ fourth-quarter 2025 earnings call, management said global biopharma clients had moved past restructuring and pipeline reprioritization and began advancing programs with more urgency as 2025 budgets were released. Management also noted that biotech funding improved in the second half of 2025, reaching a record $28 billion in the fourth quarter and helping DSA net book-to-bill improve to 1.1x.

JPMorgan’s first-quarter 2026 Biopharma Licensing and Venture Report similarly showed selective capital markets momentum, with $6.9 billion of biopharma venture funding, below $8.6 billion in first-quarter 2025 but supported by $82.7 billion of licensing activity and six biopharma initial public offerings raising $1.8 billion, already exceeding full-year 2025 IPO proceeds.

Inotiv’s DSA segment is showing similar signs of demand improvement, as noted earlier, with first-quarter 2026 DSA revenue increasing 12% year over year, net new DSA awards increasing 27% year over year and 34% on a trailing-12-month basis, and DSA book-to-bill reaching 1.16x for the quarter and 1.08x on a trailing-12-month basis.

Industrywide pressures also remain visible across preclinical CRO peers, including softer study volumes, client budget constraints and ongoing NHP-related pressure. Charles River reported full-year FY 2025 organic revenue declined 1.6%, with DSA down 2.6% organically, even as demand indicators improved. Within RMS, Charles River flagged lower NHP revenue as an approximate 200-bps headwind to 2026 growth, driven by shipment timing and reduced volume commitments from third-party clients.

Fortrea similarly described the macro backdrop as cautious but stabilizing, with funding activity rebounding in the second half of 2025, higher client engagement and shorter decision-making timelines, particularly within biotech. It still expects recovery, however, to be uneven in the first half of 2026.

Although these pressures are seen across peers, the key distinction lies in financial resilience and operational positioning. Charles River has executed more than $300 million in annualized cost savings through restructuring and has vertically integrated its NHP supply chain through the acquisitions of Noveprim in Mauritius and K.F. in Cambodia, reducing its exposure to open-market NHP sourcing volatility. By contrast, Inotiv remains exposed to third-party sourcing, tariff-related procurement costs and working capital intensity, with limited liquidity capacity to absorb volatility.

In our view, the improving sector backdrop may support DSA bookings and customer activity, but Inotiv has limited ability to bridge to the November 2026 first lien maturity through operating improvements alone. The company still needs to convert improving demand indicators into EBITDA and cash flow quickly while managing RMS volatility, covenant waivers and NHP-related working capital needs.

Regulatory Risk

Inotiv has meaningful exposure to regulatory risk, particularly within its NHP supply chain, which has already been disrupted by government enforcement actions and broader geopolitical developments. China’s decision in 2020 to halt exports of cynomolgus monkeys, a species widely used in pharmaceutical development, significantly constrained global supply.

This was further exacerbated in November 2022, when the U.S. Attorney’s Office for the Southern District of Florida brought criminal charges against employees of a key Cambodian NHP supplier, along with government officials, related to alleged illegal sourcing and trafficking, leading to the effective shutdown of the Cambodian supply. These major developments materially reduced U.S. import volumes and increased supply-chain volatility for Inotiv.

In addition, evolving regulatory policy may further pressure demand over time. In April 2025, the FDA published a roadmap to reduce reliance on animal testing in preclinical safety studies through the use of new approach methodologies, or NAMs. This shift aligns with broader regulatory and industry trends as well as ongoing pressure from animal welfare organizations such as PETA, which advocate for reduced use of animal models in research.

While Inotiv has begun investing in these capabilities, a gradual shift toward alternative testing methods could reduce long-term demand for animal-based research services, including DSA toxicology and pathology services, while also lowering demand for research animals within the RMS segment.
 

As noted earlier, Inotiv is a midmarket CRO that provides nonclinical drug discovery and development services and supplies research animals and related products to pharmaceutical, biotechnology and medical device companies as well as academic and government institutions. The company operates through two main segments:

Discovery and safety assessment, or DSA, provides discovery, translational sciences, and nonclinical safety assessment services to support drug development across small molecules, biologics and medical devices under both Good Laboratory Practice, or GLP, and non-GLP frameworks. Capabilities span bioanalytical method development, in vivo pharmacology, pharmacokinetics, drug metabolism and toxicology as well as pathology and long-term safety studies required for regulatory submissions and clinical advancement.

For DSA, revenue is overwhelmingly service-based, generated from fixed-fee and milestone-based contracts recognized over time, with a small product component primarily through the BASi brand, which sells internally developed scientific instruments and related software used in pharmacokinetic and bioanalytical research.

Research models and services, or RMS, breeds, raises and provides purpose-bred laboratory animals used in biomedical research, including small models such as rodents and large models such as NHP and rabbits. Large models such as NHPs are primarily imported from Asia and Africa, with limited domestic breeding capacity, and are housed and quarantined in U.S. facilities before shipment to clients, while rabbits are bred in both the United States and United Kingdom.

For RMS, revenue is predominantly product-driven, derived from the sale of research models and related consumables such as diets, bedding and enrichment products, supplemented by services including genetically engineered models, colony management and health monitoring. Product revenue is generally recognized at delivery, while service revenue is recognized over time.

Aggressive Acquisition History

Inotiv’s current platform is the product of an aggressive inorganic growth strategy, executing 14 acquisitions in 48 months between July 2018 and July 2022, transforming the company from a small single-site CRO into its current two-segment platform. The strategy was designed to rapidly build critical mass across the preclinical value chain, with the most transformative transaction being the Envigo acquisition in November 2021, which created the entire RMS segment.

While this strategy expanded scale and capabilities, it also increased integration complexity, drove elevated leverage and contributed to operational challenges, particularly within RMS, where supply-chain disruption and pricing volatility have weighed on margins and cash flow, as noted earlier.

According to the February 2026 investor presentation, Inotiv describes its strategic evolution across three phases:
 

• Phase 1: Acquisition and growth (2018 to 2023) built a full-service drug discovery and development CRO through M&A activity, adding access to critical supply chains and initiating organic investments to create capacity for growth.
  
   
• Phase 2: Optimization and integration (2023 to 2025) focused on integrating the acquired entities under a unified “One Inotiv” platform, consolidating the operating footprint and enhancing client satisfaction. The RMS site consolidation from 23 to 11 facilities and the insourcing of North American transportation logistics are the primary deliverables of this phase.
  
   
• Phase 3: Expansion (2025 onward) targets margin expansion through operating leverage and cost management, alongside continued organic growth and opportunistic M&A.

Inotiv’s Global Footprint

As of LTM Dec. 31, approximately 88% of Inotiv’s revenue was generated in the United States, with the Netherlands and other international markets, including the United Kingdom and Italy, each contributing roughly 6%, underscoring the company’s concentrated U.S. exposure.
 

 

 

 

According to Octus’ CLO Database, BlackRock Financial Management is the primary holder of Inotiv’s first lien term loan, with approximately $30.5 million in holdings. BlackRock also holds approximately $1.2 million of the company’s RCF, with Black Diamond Capital Management holding approximately $1 million.